ESTEVE PHARMACEUTICALS LTD

Risk Rating: MEDIUM Justification: The risk rating is primarily driven by significant data limitations rather than immediate financial distress. The detailed financial data available is severely outdated (ending April 2014), predating the company's 2021 rebranding and apparent change in ownership structure by several years. However, the company maintains active status, current filing compliance, and the backing of established pharmaceutical entities, which mitigates what would otherwise be a HIGH risk due to the stale financial data.

Key Concerns: - Severe Data Staleness: The financial history and filed accounts text provided are from 2014. A decade of financial performance, including the impact of the 2021 name change and ownership restructuring, is missing from the available evidence, making current solvency and liquidity assessments impossible based on these figures alone. - Historical Liquidity Vulnerability: Based on the 2014 data, the company exhibited a highly illiquid position. Cash reserves were minimal (£13,207), while debtors accounted for £2.08 million of the £2.76 million in current assets. This heavy reliance on receivables collection to meet £1.62 million in current liabilities presented a ongoing liquidity risk if collections faltered. - Share Capital Discrepancy: The current company overview states a share capital of £8.00, whereas the 2014 accounts detail a called-up share capital of £2,500 (10,000 shares at £0.25 each). While this likely reflects a subsequent capital restructuring or share redemption associated with the change in control, the lack of intermediate data obscures the financial mechanics and current equity position of the business.

Positive Indicators: - Strong Filing Compliance: The company's accounts are made up to 31 December 2024 and are not overdue, nor is the confirmation statement (next due 2027). This indicates good administrative health and regulatory compliance. - Corporate Backing: The PSC register shows that Riemser Pharma UK Limited owns more than 75% of the company, and Mrs Montserrat Esteve Soler owns 25-50%. Both Riemser and the Esteve name are associated with established, international pharmaceutical groups, suggesting the UK entity is part of a larger, well-capitalized corporate structure. - Historical Profitability: In the last reported period (2014), the company demonstrated a significant turnaround, moving from net assets of £555,330 in 2013 to £1,201,753 in 2014, indicating a strong operational performance in that specific year.

Due Diligence Notes: - Obtain Contemporary Accounts: It is imperative to acquire the most recent filed accounts (up to Dec 2024) from Companies House to assess the current balance sheet, cash position, and working capital management. - Ownership and Group Structure: Investigate the relationship between the current PSCs (Riemser Pharma UK Limited and Mrs Montserrat Esteve Soler) and the former 100% owner (Abbey Pharma Limited). Clarify if the 2021 rebrand to ESTEVE PHARMACEUTICALS LTD was part of an acquisition and how group support mechanisms (if any) are structured. - Debtor Management: In the historical data, trade debtors represented a massive concentration of current assets. Due diligence must confirm whether this debtor concentration has been resolved in recent years or if the business model inherently relies on extended credit terms. - Capital Restructuring: Investigate the reduction in share capital from £2,500 to £8.00 to understand if this was part of a return of capital to previous shareholders or a restructuring step, and verify the current shareholders' funds position.